6ay6: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Naegleria fowleri CYP51-voriconazole complex== | ==Naegleria fowleri CYP51-voriconazole complex== | ||
<StructureSection load='6ay6' size='340' side='right' caption='[[6ay6]], [[Resolution|resolution]] 2.40Å' scene=''> | <StructureSection load='6ay6' size='340' side='right'caption='[[6ay6]], [[Resolution|resolution]] 2.40Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[6ay6]] is a 1 chain structure with sequence from [ | <table><tr><td colspan='2'>[[6ay6]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Naegleria_fowleri Naegleria fowleri]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6AY6 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6AY6 FirstGlance]. <br> | ||
</td></tr><tr id=' | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.4Å</td></tr> | ||
<tr id=' | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CSO:S-HYDROXYCYSTEINE'>CSO</scene>, <scene name='pdbligand=HEM:PROTOPORPHYRIN+IX+CONTAINING+FE'>HEM</scene>, <scene name='pdbligand=VOR:VORICONAZOLE'>VOR</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6ay6 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ay6 OCA], [https://pdbe.org/6ay6 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6ay6 RCSB], [https://www.ebi.ac.uk/pdbsum/6ay6 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6ay6 ProSAT]</span></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | |||
</table> | </table> | ||
== Function == | |||
[https://www.uniprot.org/uniprot/A0A2H4A2U9_NAEFO A0A2H4A2U9_NAEFO] | |||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 23: | Line 23: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Large Structures]] | ||
[[Category: Abagyan | [[Category: Naegleria fowleri]] | ||
[[Category: Aksenov | [[Category: Abagyan R]] | ||
[[Category: Calvet | [[Category: Aksenov A]] | ||
[[Category: Debnath | [[Category: Calvet CM]] | ||
[[Category: Jennings | [[Category: Debnath A]] | ||
[[Category: Luth | [[Category: Jennings G]] | ||
[[Category: McKerrow | [[Category: Luth M]] | ||
[[Category: Nes | [[Category: McKerrow JH]] | ||
[[Category: Podust | [[Category: Nes WD]] | ||
[[Category: Zhou | [[Category: Podust LM]] | ||
[[Category: Zhou W]] | |||
Latest revision as of 17:28, 4 October 2023
Naegleria fowleri CYP51-voriconazole complexNaegleria fowleri CYP51-voriconazole complex
Structural highlights
FunctionPublication Abstract from PubMedPrimary Amoebic Meningoencephalitis (PAM) is caused by Naegleria fowleri, a free-living amoeba that occasionally infects humans. While considered "rare" (but likely underreported) the high mortality rate and lack of established success in treatment makes PAM a particularly devastating infection. In the absence of economic inducements to invest in development of anti-PAM drugs by the pharmaceutical industry, anti-PAM drug discovery largely relies on drug 'repurposing'-a cost effective strategy to apply known drugs for treatment of rare or neglected diseases. Similar to fungi, N. fowleri has an essential requirement for ergosterol, a building block of plasma and cell membranes. Disruption of sterol biosynthesis by small-molecule inhibitors is a validated interventional strategy against fungal pathogens of medical and agricultural importance. The N. fowleri genome encodes the sterol 14-demethylase (CYP51) target sharing ~35% sequence identity to fungal orthologues. The similarity of targets raises the possibility of repurposing anti-mycotic drugs and optimization of their usage for the treatment of PAM. In this work, we (i) systematically assessed the impact of anti-fungal azole drugs, known as conazoles, on sterol biosynthesis and viability of cultured N. fowleri trophozotes, (ii) identified the endogenous CYP51 substrate by mass spectrometry analysis of N. fowleri lipids, and (iii) analyzed the interactions between the recombinant CYP51 target and conazoles by UV-vis spectroscopy and x-ray crystallography. Collectively, the target-based and parasite-based data obtained in these studies validated CYP51 as a potentially 'druggable' target in N. fowleri, and conazole drugs as the candidates for assessment in the animal model of PAM. CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM).,Debnath A, Calvet CM, Jennings G, Zhou W, Aksenov A, Luth MR, Abagyan R, Nes WD, McKerrow JH, Podust LM PLoS Negl Trop Dis. 2017 Dec 28;11(12):e0006104. doi:, 10.1371/journal.pntd.0006104. eCollection 2017 Dec. PMID:29284029[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||||